Tiantan Bio subsidiary completes hemophilia drug trial

Beijing Tiantan Biological Products announced its subsidiary Chengdu RongSheng Pharmaceutical completed Phase I clinical trials for a recombinant coagulation factor VIII treatment for hemophilia A patients.

Results in adults and adolescents with severe hemophilia A showed 1.5-1.7 times longer half-life compared to reference drugs, with low adverse reactions. The product required RMB 909.6m in research and development investment.

Phase III trials and market approval are still required before commercialization.